---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-118664"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2025-12-05T23:59:59+00:00"
generated_at: "2026-05-16T14:15:13.690403+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Natera acquires Foresight Diagnostics for $275M upfront plus $175M earnouts

## Summary
- All-stock acquisition includes $275M upfront consideration plus up to $175M in revenue- and reimbursement-based milestone earnouts.
- Adds Foresight's PhasED-Seq phased variant technology with LOD95 of 0.3 ppm, enhancing Signatera MRD platform.
- Expands Natera's presence in lymphoma, with Foresight's CLARITY MRD assay used in three prospective trials and NCCN guideline inclusion.
- Integration of phased variants into Signatera platform expected to be launched for clinical use in 2026.
- Company issued 1,127,982 shares upfront and up to ~824,583 additional contingent shares; will file registration for resale.

## SEC filing metadata
- accession: 0001104659-25-118664
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2025-12-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465925118664/0001104659-25-118664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465925118664/tm2532406d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-118664
- JSON: https://secwatch.observer/filing/0001104659-25-118664.json
- Plain text: https://secwatch.observer/filing/0001104659-25-118664.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.